Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte responses via peptide-MHC tetrameric complexes assay |
| |
Authors: | Lee Tzong-Hsien Chuang Yen-Ling Tsai Sun-Lung Liaw Yun-Fan |
| |
Institution: | (1) Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan |
| |
Abstract: | Summary Lamivudine, an oral nucleoside analogue, inhibits hepatitis B virus (HBV) replication. It has been shown to be able to restore
T cell responsiveness and to induce a type 1 T helper cell (Th 1) immunity in chronic HBV patients. To further examine the
effects of lamivudine on cytotoxic T Imphocyte (CTL), responses, two HBV antigenic peptide-HLA-A2 tetrameric complexes containing
peptides derived from HBV core protein (residues 18–27; FLPSDFFPSV) and polymerase (residue 551–559; YMDDVVLGA) were constructed.
These two tetramers were used to serially determine the frequency of HBV antigen-specific CD8+ T cells before and during the treatment of lamivudine. The specificity of these tetramers was confirmed by (a) nonstaining
of CD8+ T cells from HLA-A2-negative HBV patients, (b) having variable frequency data in the different teteramer measurement, and
(c) showing peptide-specific CTL activity in the sorted tetramer-stanining CD8+T cells. Low frequency of HBV-specific CTLs was measured for both tetramers before lamivudine treatment. However, the number
of CD8+ T cells specific for HBV core 18–27 increased significantly during lamivudine treatment. In contrast, relatively lower frequency
of HBV pol 551–559 specific CD8+T cells was persistently measured after lamivudine treatment. These results indicated that the lamivudine treatment could
enhance HBV specific CTL responses. |
| |
Keywords: | cytotoxic T lymphocyte response Hepatitis B virus HLA-peptide tetramer complexes lamivudine |
本文献已被 SpringerLink 等数据库收录! |
|